A Phase II Open-Label, Multi-Centre Study of Minimal Residual Disease-Directed Consolidation with Epcoritamab or Epcoritamab-Lenalidomide-Rituximab Post Anti-CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma (NCT06414148)
EpLCART
This trial is No longer recruiting
Registration number NCT06414148
Program & service
This trial is being run with the Cancer service, and as part of the Haematology program.
Trial phase
Phase 2
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Shafqat Inam
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR